Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Martinsried/Munich, October 31, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) announces that Dr. Thomas Strüngmann, Managing Director of Santo Holding (Germany) GmbH, will resign from his role as a Supervisory Board member of MediGene AG for personal reasons, effective from January 1, 2009.
Prof. Dr. Ernst-Ludwig Winnacker, Chairman of MediGene's Supervisory Board commented: "We very much regret the fact that Dr. Strüngmann has resigned from office. He showed great commitment on our Supervisory Board, and through his expertise he contributed significantly to the refocusing of our company's strategy. On behalf of both our Supervisory and Executive Boards, I would like to express my heartfelt thanks to him."
This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademark of MediGene AG. This trademark may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, two of which providing a very high sales potential. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.
Contact MediGene AG E-mail: investor@medigene.com Fax: +49 - 89 - 85 65 - 2920 Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85 65 - 3324 Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946
--- End of Message ---
MediGene AG Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090; ISIN: DE0005020903 ; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;
